Clinical Trial

Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers

Study acronym: PANCOV
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France. 48 participants divided into 4 cohorts will be included in the trial. Primary objectives are the following: * To determine the safety and reactogenicity of different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, in healthy volunteers between Day 0 and Month1 * To determine the humoral immune response (neutralizing antibody titers) induced by different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, at Month1 after administration
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-06
notable Primary completion pushed: 2026-06-25 -> 2026-10-08 2026-05-06
Trial Details
NCT Number NCT07113106
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France, Unité Mixte de Service 54 Methods and Applied Research for Trials (UMS 54 MART)
Conditions Healthy Volunteers
Enrollment 48 participants
Start Date 2025-06-18
Primary Completion 2026-10-08 (estimated)
Study Completion 2027-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-05